Home > Boards > US Listed > Biotechs > Contrafect Corp (CFRX)

I am buying today seems a good price

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Blutribe Member Profile
 
Followed By 76
Posts 3,977
Boards Moderated 0
Alias Born 08/09/04
160x600 placeholder
ContraFect Announces ASM Microbe 2019 Outstanding Abstract Award and Presentation of New Data GlobeNewswire Inc. - 6/17/2019 5:00:00 PM
Antimicrobials Working Group Commends Senator Isakson and Senator Casey for Introducing Legislation to Improve Access to Inno... PR Newswire (US) - 6/7/2019 9:27:00 AM
ContraFect Awarded $7.2 Million USAMRDC Grant to Support the Advancement of Lysin Candidate CF-296 GlobeNewswire Inc. - 6/6/2019 7:00:00 AM
ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium GlobeNewswire Inc. - 6/3/2019 7:00:00 AM
ContraFect Announces Publication of Paper on Recent Exebacase Data in Antimicrobial Agents and Chemotherapy Journal GlobeNewswire Inc. - 5/31/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/29/2019 5:02:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2019 4:35:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2019 4:33:52 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2019 4:27:39 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2019 4:25:03 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/29/2019 4:22:57 PM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 5/13/2019 5:30:16 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2019 4:24:58 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/10/2019 4:13:39 PM
ContraFect Reports First Quarter 2019 Financial Results and Provides Business Update GlobeNewswire Inc. - 5/10/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/9/2019 4:53:42 PM
ContraFect to Host R&D Symposium on Direct Lytic Agents (Lysins and Amurins) with Clinical Thought Leaders on Infectious Dise... GlobeNewswire Inc. - 5/8/2019 7:00:00 AM
ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Mi... GlobeNewswire Inc. - 4/16/2019 5:15:00 AM
Antimicrobials Working Group Highlights Member Company Participation at the 29th European Congress of Clinical Microbiology a... PR Newswire (US) - 4/12/2019 10:08:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 4/10/2019 1:30:46 PM
ContraFect Announces Publication of Exebacase Data in Antimicrobial Agents and Chemotherapy Journal GlobeNewswire Inc. - 4/8/2019 7:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/4/2019 1:30:22 PM
ContraFect Announces Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) GlobeNewswire Inc. - 4/4/2019 7:00:00 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/2/2019 5:24:25 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/2/2019 5:20:14 PM
Blutribe   Monday, 02/11/19 11:26:55 AM
Re: Sugarplum post# 96
Post # of 117 
I am buying today seems a good price and value given the recent pullback and news...


YONKERS, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life-threatening, drug-resistant infectious diseases, today announced that the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded the Company $2.3 million in additional funding over the course of the next two years. The Company will use the grant for the development of lysin therapeutics to treat serious, potentially life-threatening invasive infections caused by antibiotic-resistant Pseudomonas aeruginosa (P. aeruginosa), a virulent Gram-negative pathogen. This is an increase to the original CARB-X option amount of $1.0 million, part of the Company’s grant from CARB-X in March of 2017.

“We are pleased to have been awarded this additional funding from CARB-X. This follows our recent announcement of positive topline data from the Phase 2 trial of our lead lysin candidate exebacase, or CF-301, for the treatment of Staph aureus bacteremia, including endocarditis, which establishes clinical proof of concept for lysins as therapeutic agents. P. aeruginosa is a major cause of morbidity and mortality, often related to hospital acquired pneumonia, and is a major medical challenge, particularly for patients with cystic fibrosis. We look forward to advancing this program into the clinic as rapidly as possible,” said Cara Casino, M.D., Executive Vice President of Research & Development and Chief Medical Officer of ContraFect.

“We view this additional funding from CARB-X as continued validation of our novel lysin platform, which underscores the opportunity to combat highly resistant Gram-negative pathogens, considered to be the greatest threats to global health by both the CDC and WHO, with our proprietary lysin candidates.” said Steven C. Gilman, Ph.D., Chairman and Chief Executive Officer of ContraFect.

About CARB-X:

CARB-X is the world's largest public-private partnership devoted to antibacterial preclinical R&D. Funded by BARDA, Wellcome Trust, and NIAID, it will spend $450 million from 2017-2021 to support innovative products moving towards human clinical trials. CARB-X focuses on high priority drug-resistant bacteria, especially Gram-negative organisms. CARB-X is a charitable global public-private partnership led by Boston University School of Law. Other partners include the Broad Institute of Harvard and MIT, MassBio, the California Life Sciences Institute and RTI International. For more information, please visit www.carb-x.org and follow them on Twitter @CARB-X.

Buy OVERSOLD, sell OVERBOUGHT...Deep Pockets, so when I begin buying, watch out above! TECHNICAL and FUNDAMENTAL trader..
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist